SELLAS Life Sciences (SLS) Amortization of Deferred Charges (2017 - 2021)

SELLAS Life Sciences (SLS) has 3 years of Amortization of Deferred Charges data on file, last reported at $846000.0 in Q1 2021.

• Quarterly Amortization of Deferred Charges changed N/A year-over-year to $846000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $846000.0 (changed N/A YoY) and the FY2020 annual result came in at $282000.0, changed N/A from the prior year.
• Amortization of Deferred Charges improved to $846000.0 in Q1 2021 per SLS's latest filing, from $19000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $846000.0 in Q1 2021 and bottomed at -$258000.0 in Q4 2017.
• The 3-year median for Amortization of Deferred Charges is $57500.0 (2018), against an average of $163333.3.
• Peak annual rise in Amortization of Deferred Charges reached 63.18% in 2018, while the deepest fall reached 63.18% in 2018.
• Tracing SLS's Amortization of Deferred Charges over 3 years: stood at -$258000.0 in 2017, then jumped by 107.36% to $19000.0 in 2018, then soared by 4352.63% to $846000.0 in 2021.
• Per Business Quant, the three latest SLS Amortization of Deferred Charges figures stand at $846000.0 (Q1 2021), $19000.0 (Q3 2018), and $95000.0 (Q2 2018).

Peer Comparison